About Vivus, inc.
VIVUS, Inc. is a pharmaceutical company that is committed to providing innovative solutions for patients with serious medical conditions and life-limiting diseases. The company was founded in 1991 and has since been at the forefront of developing cutting-edge therapies that improve patient outcomes.
At VIVUS, the focus is on addressing unmet medical needs through research and development of novel treatments. The company's portfolio includes products for obesity, erectile dysfunction, and sleep apnea, among others.
One of VIVUS' most notable products is Qsymia®, a prescription weight-loss medication that has been approved by the FDA. Qsymia® works by suppressing appetite and reducing food cravings, making it easier for patients to stick to a healthy diet plan. This medication has shown significant results in clinical trials, with patients losing an average of 10% of their body weight within one year.
Another product in VIVUS' portfolio is STENDRA® (avanafil), an oral medication used to treat erectile dysfunction (ED). STENDRA® works quickly and effectively by increasing blood flow to the penis during sexual stimulation. Clinical studies have shown that STENDRA® can help men achieve erections within 15 minutes after taking the medication.
In addition to these products, VIVUS also offers a range of other therapies designed to improve patient outcomes across various therapeutic areas. These include medications for sleep apnea, pulmonary arterial hypertension (PAH), and more.
At VIVUS, innovation is key. The company invests heavily in research and development efforts aimed at discovering new treatments for unmet medical needs. This commitment has led to numerous breakthroughs over the years – including several FDA-approved medications – as well as ongoing clinical trials exploring new treatment options.
Overall, VIVUS' dedication to improving patient outcomes through innovative therapies makes it a leader in the pharmaceutical industry today. With its strong track record of success and ongoing commitment to research excellence, this company will undoubtedly continue making significant contributions towards advancing healthcare worldwide in years ahead!